RB1 and cancer: Integrating multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, could further enhance our understanding of RB1-deficient cancers and facilitate the development of personalized treatment strategies tailored to individual patients’ molecular profiles.